Surveying The Cannabis Patent Litigation Landscape

By Tryn Stimart and Jean Dassie (September 17, 2018, 2:00 PM EDT) -- Cannabis is federally listed as a Schedule 1 drug pursuant to the Controlled Substances Act.[1] The classification is reserved for drugs with a "high potential for abuse and the potential to create severe psychological and/or physical dependence" and with "no currently accepted medical use."[2] Notwithstanding, the cannabis industry is booming and projected to continue growing. A recent study found that spending on legal cannabis worldwide is expected to hit $57 billion by 2027.[3] The largest group of buyers will be in North America, projected to grow from $9.2 billion in 2017 to $47.3 billion in 2027.[4]...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!